Immunization of turkeys with a DNA vaccine expressing the haemagglutinin gene of low pathogenic avian influenza virus subtype H9N2

Shehata, Awad A.; Basiouni, Shereen; Ali, Ahmed; Fawzy, Mohamed; Hafez, Hafez M.; Ulbert, Sebastian; Vahlenkamp, Thomas W.

doi:10.1016/j.jviromet.2020.113938

Cited by 7 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, pVax1 features a kanamycin resistance gene for selection to avoid allergic responses associated with ampicillin as well as a human CMV promoter and BGH polyadenylation signal for efficient DNA expression and mRNA transcription termination, respectively [ 18 ]. Recently, the vector has been used in platforms showing enhanced protection from Japanese Encephalitis Virus, influenza H9N2, Dengue virus, Crimean-Congo Hemorrhagic Fever Virus, and anti-tumor applications, [ 19 , 20 , 21 , 22 , 23 ]. These DNA vaccines were able to elicit high titers of protective antibody [ 19 , 20 , 21 , 22 ] suggesting this approach may also be effective for COVID-19.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, the vector has been used in platforms showing enhanced protection from Japanese Encephalitis Virus, influenza H9N2, Dengue virus, Crimean-Congo Hemorrhagic Fever Virus, and anti-tumor applications, [ 19 , 20 , 21 , 22 , 23 ]. These DNA vaccines were able to elicit high titers of protective antibody [ 19 , 20 , 21 , 22 ] suggesting this approach may also be effective for COVID-19. Importantly, none of these studies reported negative side effects associated with use of the pVax1 vector [ 19 , 20 , 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…These DNA vaccines were able to elicit high titers of protective antibody [ 19 , 20 , 21 , 22 ] suggesting this approach may also be effective for COVID-19. Importantly, none of these studies reported negative side effects associated with use of the pVax1 vector [ 19 , 20 , 21 , 22 ]. As a major concern of vaccine production is safety, the use of pVax1 and its positive history in vaccine investigation was an important aspect of our plasmid design.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

An Intramuscular DNA Vaccine for SARS-CoV-2 Decreases Viral Lung Load but Not Lung Pathology in Syrian Hamsters

et al. 2021

View full text Add to dashboard Cite

The 2019 novel coronavirus, SARS-CoV-2, first reported in December 2019, has infected over 102 million people around the world as of February 2021 and thus calls for rapid development of safe and effective interventions, namely vaccines. In our study, we evaluated a DNA vaccine against SARS-CoV-2 in the Syrian hamster model. Hamsters were vaccinated with a DNA-plasmid encoding the SARS-CoV-2 full length spike open reading frame (ORF) to induce host cells to produce spike protein and protective immune responses before exposure to infectious virus. We tested this vaccine candidate by both intranasal (IN) and intramuscular (IM) routes of administration and complexing with and without an in vivo delivery reagent. Hamsters receiving prime-boost-boost IM-only vaccinations recovered body weight quicker, had decreased lung viral loads, and increased SARS-CoV-2-specific antibody titers compared to control vaccinated animals but, surprisingly, lung pathology was as severe as sham vaccinated controls. The IM/IN combination group showed no efficacy in reducing lung virus titers or pathology. With increasing public health need for rapid and effective interventions, our data demonstrate that in some vaccine contexts, significant antibody responses and decreased viral loads may not be sufficient to prevent lung pathology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An Intramuscular DNA Vaccine for SARS-CoV-2 Decreases Viral Lung Load but Not Lung Pathology in Syrian Hamsters

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Avian influenza virus (AIV) is a highly contagious virus that causes substantial morbidity and mortality in poultry populations, and some strains pose a possible pandemic threat to humans [34,94]. Despite the wide use of several inactivated AIV vaccines, they have proven ineffective, necessitating the development of new technology to improve their immunogenicity and enhance their effectiveness.…”

Section: Avian Influenza Virusmentioning

confidence: 99%

Nanoparticles as a novel and promising antiviral platform in veterinary medicine

et al. 2021

Self Cite

View full text Add to dashboard Cite

Traditional veterinary virus vaccines, such as inactivated and live-attenuated vaccines, have achieved tremendous success in controlling many viral diseases of livestock and chickens worldwide. However, many recent viral outbreaks caused by different emerging and re-emerging viruses continue to be reported annually worldwide. It is therefore necessary to develop new control regimens. Nanoparticle research has received considerable attention in the last two decades as a promising platform with significant success in veterinary medicine, replacing traditional viral vector vaccines. However, the field of nanoparticle applications is still in its initial phase of growth. Here, we discuss various preparation methods, characteristics, physical properties, antiviral effects, and pharmacokinetics of well-developed nanoparticles and the potential of nanoparticles or nano-vaccines as a promising antiviral platform for veterinary medicine.

show abstract

“…The concept of nucleic acid vaccine is to deliver target antigen DNA or RNA to cells of the immune system ( 22 , 23 ). Use of mRNA COVID-19 vaccine has been permitted and the immunization programs have been carried out in several countries around the world since 2020 ( 24 ).…”

Section: Introductionmentioning

confidence: 99%

Hemagglutinin expressed by yeast reshapes immune microenvironment and gut microbiota to trigger diverse anti-infection response in infected birds

Xie

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionThe H5N8 influenza virus is a highly pathogenic pathogen for poultry and human. Vaccination is the most effective method to control the spread of the virus right now. The traditional inactivated vaccine, though well developed and used widely, is laborious during application and more interests are stimulated in developing alternative approaches.MethodsIn this study, we developed three hemagglutinin (HA) gene-based yeast vaccine. In order to explore the protective efficacy of the vaccines, the gene expression level in the bursa of Fabricius and the structure of intestinal microflora in immunized animals were analyzed by RNA seq and 16SrRNA sequencing, and the regulatory mechanism of yeast vaccine was evaluated.ResultsAll of these vaccines elicited the humoral immunity, inhibited viral load in the chicken tissues, and provided partial protective efficacy due to the high dose of the H5N8 virus. Molecular mechanism studies suggested that, compared to the traditional inactivated vaccine, our engineered yeast vaccine reshaped the immune cell microenvironment in bursa of Fabricius to promote the defense and immune responses. Analysis of gut microbiota further suggested that oral administration of engineered ST1814G/H5HA yeast vaccine increased the diversity of gut microbiota and the increasement of Reuteri and Muciniphila might benefit the recovery from influenza virus infection. These results provide strong evidence for further clinical use of these engineered yeast vaccine in poultry.

show abstract

Immunization of turkeys with a DNA vaccine expressing the haemagglutinin gene of low pathogenic avian influenza virus subtype H9N2

Cited by 7 publications

References 39 publications

An Intramuscular DNA Vaccine for SARS-CoV-2 Decreases Viral Lung Load but Not Lung Pathology in Syrian Hamsters

An Intramuscular DNA Vaccine for SARS-CoV-2 Decreases Viral Lung Load but Not Lung Pathology in Syrian Hamsters

Nanoparticles as a novel and promising antiviral platform in veterinary medicine

Hemagglutinin expressed by yeast reshapes immune microenvironment and gut microbiota to trigger diverse anti-infection response in infected birds

Contact Info

Product

Resources

About